The Bcl-2 family includes 26 proteins involved in apoptosis. Cancer cells can develop the
ability to avoid apoptosis through the upregulation and/or down regulation of such proteins Bax, Bcl-xL or Mcl-1, especially
during chemoresistance progress. These proteins engaged in a network of dynamic interactions that control apoptosis
triggering have become attractive therapeutic targets in cancers including melanoma. Among them, the Bax/Bcl-xL interaction
appears critical in maintaining mitochondria integrity. Therefore a series of mixed polyphenol-heterocyclic
molecules, were rationally designed by molecular docking as Bax/Bcl-xL inhibitors. It has been screened against B16-F10
melanoma cancer cells for a preliminary investigation of their cytotoxicity. All these compounds exhibited a significant
cytotoxicity against these cancer cells, in the 0.3-6 M range. A pyrazole-type molecule, which had a submicromolar IC50
value with an excellent selectivity index (14), is the most promising derivative for further development.
Bcl-2 家族包括 26 种参与细胞凋亡的蛋白质。癌细胞可以通过上调和/或下调 Bax、Bcl-xL 或 Mcl-1 等蛋白来避免凋亡,尤其是在化疗抗药性进展期间。这些参与控制细胞凋亡触发的动态相互作用网络的蛋白质已成为包括
黑色素瘤在内的癌症的诱人治疗靶点。其中,Bax/Bcl-xL 的相互作用似乎对维持线粒体的完整性至关重要。因此,我们通过分子对接合理地设计了一系列混合多
酚杂环分子,作为 Bax/Bcl-xL
抑制剂。针对 B16-F10
黑色素瘤癌细胞进行了筛选,对其细胞毒性进行了初步研究。所有这些化合物在 0.3-6 M 的范围内对这些癌细胞都有明显的细胞毒性。一种
吡唑类分子的 IC50 值为亚摩尔级,具有极佳的选择性指数 (14),是最有希望进一步开发的衍
生物。